374 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Conditions: Endometrial Serous Adenocarcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC1 Uterine Corpus Cancer;   Stage IIIC2 Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
22 Recruiting Prospective Analysis of Robot-Assisted Surgery
Conditions: Esophageal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Rectal Cancer;   Bladder Cancer;   Prostate Cancer;   Renal Cancer;   Uterus Cancer;   Head and Neck Cancer;   Lung Cancer
Interventions: Procedure: Robot-assisted surgery;   Procedure: Conventional Surgery
23 Recruiting Diet and Physical Activity in Uterine Cancer Survivors
Condition: Endometrial Neoplasms
Intervention: Behavioral: Shape-Up following cancer treatment
24 Recruiting Improving the Treatment for Women With Early Stage Cancer of the Uterus
Conditions: Complex Endometrial Hyperplasia With Atypia;   Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Drug: Levonorgestrel;   Drug: Metformin
25 Recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
26 Recruiting Lymphedema After Primary Surgery for Endometrial Cancer
Conditions: Carcinoma of the Endometrium;   Hysterectomy;   Lymphadenectomy
Intervention: Procedure: Lymphadenectomy
27 Recruiting Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer
Interventions: Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation Therapy
28 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin
29 Not yet recruiting Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy
Condition: Endometrial Polyps
Interventions: Procedure: Hysteroscopic morcellation;   Procedure: Standard hysteroscopic resection
30 Recruiting Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
Conditions: Cervical Carcinoma;   Ovarian Carcinoma;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
Interventions: Procedure: Supportive Care;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
31 Recruiting Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
Conditions: Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions: Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
32 Recruiting Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Other: Comprehensive Geriatric Assessment;   Other: Questionnaire Administration
33 Recruiting Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Condition: Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Interventions: Drug: Pazopanib plus Gemcitabine;   Drug: Pazopanib
34 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
35 Recruiting Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Intervention: Radiation: Radiotherapy
36 Recruiting Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Conditions: Endometrial Adenocarcinomas;   Neuroendocrine Tumors;   Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)
Interventions: Drug: lurbinectedin (PM01183);   Drug: Doxorubicin
37 Recruiting Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Conditions: Endometrial Atypical Hyperplasia;   Endometrial Adenocarcinoma
Interventions: Drug: Megestrol acetate and metformin;   Drug: Megestrol acetate
38 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
39 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
40 Recruiting A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Condition: Adenocarcinoma of the Endometrium
Intervention: Drug: Metformin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years